Abstract
The development of synthetic macrocycles represents a powerful approach toward the identification of new protein binders or inhibitors of Protein-Protein Interactions (PPI) which are known to play key biological roles in cancer signaling as well as in the regulation of cell division cycle. Structural investigations led to identify “hot loops” sharing common motifs that are mainly involved in PPIs. Most PPIs occur through large and flat surfaces; currently these protein complexes are defined as “undruggable” by conventional drug-discovery approaches, since the identification of small molecules to inhibit these targets is often unreachable.
Typically macrocycles are 500-2000 Da in size, having 12-membered, or more, ring architecture: they do not obey the Lipinski’s rule but, for them nature offers many examples as therapeutic agents such as erythromycin (antibiotic), cyclosporin (immunosuppressant) and somatostatin (hormone).
Peptide-based macrocycles offer the advantages of directly mimicking secondary structures involved in PPIs and their pharmacological application is related to the potential improvement of lead peptides in terms of potency, selectivity, stability and cell permeation.
The promising relevance of cyclopeptides prompted to develop new synthetic methods for cyclization: often biotechnological approaches as well as regioselective reactions have been employed to cyclize peptides rapidly and nearly quantitatively. Moreover, different synthetic strategies in peptidomimetics’ macrocyclization are actually available based on surrogate peptide bonds or NCL (Native Chemical Ligation) methods.
In this review we focus on the most common methods for the preparation of cyclopeptides and interesting applications of the last decade.
Keywords: Protein-Protein Interactions, Macrocycles, Cyclopeptides.
Current Medicinal Chemistry
Title:Targeting “Undruggable” Proteins: Design of Synthetic Cyclopeptides
Volume: 23 Issue: 8
Author(s): Anna Russo, Carmela Aiello, Paolo Grieco and Daniela Marasco
Affiliation:
Keywords: Protein-Protein Interactions, Macrocycles, Cyclopeptides.
Abstract: The development of synthetic macrocycles represents a powerful approach toward the identification of new protein binders or inhibitors of Protein-Protein Interactions (PPI) which are known to play key biological roles in cancer signaling as well as in the regulation of cell division cycle. Structural investigations led to identify “hot loops” sharing common motifs that are mainly involved in PPIs. Most PPIs occur through large and flat surfaces; currently these protein complexes are defined as “undruggable” by conventional drug-discovery approaches, since the identification of small molecules to inhibit these targets is often unreachable.
Typically macrocycles are 500-2000 Da in size, having 12-membered, or more, ring architecture: they do not obey the Lipinski’s rule but, for them nature offers many examples as therapeutic agents such as erythromycin (antibiotic), cyclosporin (immunosuppressant) and somatostatin (hormone).
Peptide-based macrocycles offer the advantages of directly mimicking secondary structures involved in PPIs and their pharmacological application is related to the potential improvement of lead peptides in terms of potency, selectivity, stability and cell permeation.
The promising relevance of cyclopeptides prompted to develop new synthetic methods for cyclization: often biotechnological approaches as well as regioselective reactions have been employed to cyclize peptides rapidly and nearly quantitatively. Moreover, different synthetic strategies in peptidomimetics’ macrocyclization are actually available based on surrogate peptide bonds or NCL (Native Chemical Ligation) methods.
In this review we focus on the most common methods for the preparation of cyclopeptides and interesting applications of the last decade.
Export Options
About this article
Cite this article as:
Russo Anna, Aiello Carmela, Grieco Paolo and Marasco Daniela, Targeting “Undruggable” Proteins: Design of Synthetic Cyclopeptides, Current Medicinal Chemistry 2016; 23 (8) . https://dx.doi.org/10.2174/0929867323666160112122540
DOI https://dx.doi.org/10.2174/0929867323666160112122540 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Cell Permeability-Glycoprotein as a Target of MDR Reverters: Possible Role of Novel Dihydropyridine Derivatives
Current Drug Targets Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms
Current Drug Targets Adenocarcinoma of the Appendix in Elderly: Diagnostic Dilemma
New Emirates Medical Journal Naturally Occurring δ-Hydroxy-γ-Lactones: Muricatacins and Related Compounds
Current Organic Chemistry Bone Metastases Radiopharmaceuticals: An Overview
Current Radiopharmaceuticals HSV Amplicons: Neuro Applications
Current Gene Therapy Another Brick in the Wall: Innate Lymphoid Cells of the Intestine
Current Immunology Reviews (Discontinued) Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication
Anti-Cancer Agents in Medicinal Chemistry Myokines in Myogenesis and Health
Recent Patents on Biotechnology Epigenetics in Brain Tumors: HDACs Take Center Stage
Current Neuropharmacology Parallel Gene Expression Profiling of Mantle Cell Lymphoma – How Do We Transform ´Omics Data into Clinical Practice
Current Genomics Induction of Tumour Cell Senescence: A New Strategy in Anticancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders What Does Systems Biology Mean for Drug Development?
Current Medicinal Chemistry A Systems Biology Consideration of the Vasculopathy of Sickle Cell Anemia: The Need for Multi-Modality Chemo-Prophylaxis
Cardiovascular & Hematological Disorders-Drug Targets Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Current Pharmaceutical Biotechnology Anti-inflammatory, Antioxidant, Lung and Liver Protective Activity of <i>Galaxaura oblongata</i> as Antagonistic Efficacy against LPS using Hematological Parameters and Immunohistochemistry as Biomarkers
Cardiovascular & Hematological Agents in Medicinal Chemistry Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases
Current Gene Therapy